July 24, 2017
The presence of hepatitis B core antibody, or HBcAb, did not affect the outcomes of hepatic resection in patients with either hepatitis C-related or non-B, non-C hepatocellular carcinoma, according to results of a recent study. However, the data showed a possible link between occult hepatitis B infection and hepatocarcinogenesis in patients with non-B, non-C HCC.
“Because measurement of HBcAb is not included in the regular screening protocol for HBV infection at many institutions, the actual prognostic influence of HBcAb-positivity in HCC patients remains unclear,” Shinji Itoh, MD, PhD, from the Graduate School of Medical Sciences, Fukuoka, Japan, and colleagues wrote. “Given the apparently high proportion of patients with a history of HBV, the clinical features of the HBcAb-positive subgroup of [non-B, non-C] HCC or HCV-related HCC patients need to be explored to allow for better clinical management of HCC.”